Lv11
88 积分 2023-07-12 加入
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
7天前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
7天前
已完结
Claudin 18.2 as a novel therapeutic target
8天前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
9天前
已完结
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer
12天前
已完结
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
12天前
已完结
Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis
14天前
已完结
Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression
23天前
已完结
Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer
28天前
已完结
Cancer incidence and mortality in China, 2024
1个月前
已完结
皖公网安备34019202002308
